Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Approvable letter for new Arixtra indications

Feb. 5, 2007

Recent patents impart novel agents for treating hematological disorders

Feb. 2, 2007

Bayer to discontinue non-CABG studies of Trasylol

Jan. 29, 2007

Novel agents for thrombotic disorders disclosed in recent Pfizer and Bristol-Myers Squibb patents

Jan. 24, 2007

Pivotal study of prasugrel in acute coronary syndrome completes enrollment

Jan. 18, 2007

Novel TAFIa inhibitor profiled at Berlex

Jan. 16, 2007

Recent AstraZeneca patents describe novel therapeutic agents for thrombotic disorders

Jan. 15, 2007

Biogen Idec to acquire Syntonix

Jan. 5, 2007

ARC-1779 begins phase I program

Jan. 5, 2007

REG1 anticoagulant system safe in humans

Jan. 4, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....